KidneyCAN News
Read on!
The 2022 Kidney Cancer Research Summit
Dr. Laurence Albiges (Institut Gustave Roussy) presents on the microbiome at KCRS22. The microbiome has now been recognized as one of the emerging hallmarks and enabling characteristics of cancer. KidneyCAN hosted the 4th Annual Kidney Cancer...
Debra Beyhan: Embracing the Ups and Downs of Life with Kidney Cancer
Deb Beyhan is the Patient Legislative Advocate for KidneyCAN. She was diagnosed with stage IV kidney cancer in 2016 at the age of 53. Deb lives outside of Atlanta, GA, with her husband. For this month's Community Spotlight, we want to tell you...
District Days: Asking Congress to Fund Kidney Cancer Research
On August 8-9th, KidneyCAN gathered advocates from all over the United States to ask Congress for robust funding for kidney cancer research through the NIH and CDMRP (Congressionally Directed Medical Research Programs). Read on to hear about our...
Michael Whitley: A Kidney Cancer Diagnosis “Cracked Me Open”
Michael Whitley is 45 years old and lives in Huntsville, Alabama, with his boyfriend, Michael Mueller. He's the owner and Chief Operating Officer of EngeniusMicro, a techonology-development company focused on defense contracting. Following his...
Dr. Brandon Manley: Physician, Scientist, Advocate
Brandon Manley, M.D., is a urologic oncologist who specializes in genitourinary oncology, with a focus on patients with kidney cancer. He currently practices at Moffitt Cancer Center in Tampa, Florida, where he lives with his wife Aimee, and his...
Remembering Ralph: Time Well Spent
Ralph Knapp was diagnosed in 2014 with stage IV kidney cancer and used the opportunity to increase research funding and bring hope to patients everywhere. With heavy hearts and profound sadness, we announce the passing of Ralph Knapp, a founder of...
KidneyCAN Newsletters
KidneyCAN publishes six newsletters a year. We share the latest research news, inspiring patient and researcher stories, and KidneyCAN events — Kidney Cancer Research Summit, Town Halls, and other patient education and clinical trial opportunities.
You can view archived newsletters here. Note: research news from older issues may be outdated.
Subscribe to our newsletter to stay in the loop!
February 2023
2023 has come roaring in, and we have so much to share with you in this newsletter! Read on for all the kidney cancer updates:
- Town Hall event recap (and save the date for our next event)
- The latest research news from ASCO #GU23
- Spring Kidney Cancer Advocacy Days
- March Kidney Cancer Awareness Month
Community Spotlight - KCRS23: Call for Abstracts
December 2022
Here Comes 2023!
As 2022 winds down, we want to reflect on some of the highlights as we pursued our mission to accelerate cures for kidney cancer.
KidneyCAN hosted three patient-focused Town Hall events, two Facebook Live webinars, and participated in many other educational events to help patients and caregivers connect to support and resources.
October 2022
So many reasons to be hopeful! KidneyCAN’s first annual Rock the Run fundraiser, with amazing patient stories. The 4th Kidney Cancer Research Summit — recap, research highlights, video, and registration for KCRS23. ESMO research highlights in patient-friendly language. Community spotlight: Deb Beyhan, our legislative patient advocate, and her story of fighting stage IV kidney cancer for six years and counting. Read for all the latest news and updates!
August 2022
2022 Kidney Cancer Research Summit.
We are getting closer to our annual research conference, KCRS22, where KidneyCAN gathers many of the best kidney cancer researchers in the world to share their work and collaborate.
KCRS is a meeting focused on basic science, translational, and clinical research in kidney cancer. All are welcome to join us virtually for the hybrid event: patients, caregivers, doctors, and researchers.
June 2022
Clinical Trials for Kidney Cancer Patients
Will you need early access to new drugs at some point in your care? NOW is the time to start learning about clinical trials and when they might be right for you. Trial candidates include patients starting their first treatment, or patients who have progressed through many treatment options. Only about half of all kidney cancer patients report having a trial suggested as an option.
